SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/6EED3BB3D8729D71B8388E3ED33A4AB527B724BB54507D266413CE5DE027AB7BD813F7F7CB6051BE96371D0D2D391AF1>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/6EED3BB3D8729D71B8388E3ED33A4AB527B724BB54507D266413CE5DE027AB7BD813F7F7CB6051BE96371D0D2D391AF1
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/6EED3BB3D8729D71B8388E3ED33A4AB527B724BB54507D266413CE5DE027AB7BD813F7F7CB6051BE96371D0D2D391AF1
http://www.w3.org/2000/01/rdf-schema#comment
"FcgammaRIIIa V allele-restricted pathological complete response benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ breast cancer."
xsd:string
http://purl.uniprot.org/uniprot/#_6B11F47ADA107F505FA1B6FEAB2B9F3FE6B9FCD0E5AF5365C544EB9F154BD11EDAE0F87EC18747D8D2275052C1DA0D60
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/6EED3BB3D8729D71B8388E3ED33A4AB527B724BB54507D266413CE5DE027AB7BD813F7F7CB6051BE96371D0D2D391AF1
http://purl.uniprot.org/uniprot/Q9UN20
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6EED3BB3D8729D71B8388E3ED33A4AB527B724BB54507D266413CE5DE027AB7BD813F7F7CB6051BE96371D0D2D391AF1
http://purl.uniprot.org/uniprot/#_Q9UN20-mappedCitation-27378608
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6EED3BB3D8729D71B8388E3ED33A4AB527B724BB54507D266413CE5DE027AB7BD813F7F7CB6051BE96371D0D2D391AF1